We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 127

Brexit: Life Sciences implications
  • Bird & Bird
  • European Union, United Kingdom
  • January 24 2017

On 23 June 2016, the UK public voted to leave the EU. The Prime Minister subsequently announced an intention to serve notice of withdrawal under


End of German Olanzapine battle: Federal Supreme Court upholds patent
  • Bird & Bird
  • Germany
  • March 11 2009

On December 16, 2008 the Federal Supreme Court gave its judgment determining the validity of the Olanzapine patent, this was further to its revocation by the Federal Patent Court at first instance


Edwards Lifesciences AG v Cook Biotech Incorporated
  • Bird & Bird
  • United Kingdom
  • July 17 2009

Mr Justice Kitchin handed down a decision only four weeks after the hearing, finding Cook’s patent invalid and not infringed by Edwards’ SAPIEN heart valve


UK Patents Court allows supplementary protection certificate for combination product: Gilead Sciences, Inc’s application
  • Bird & Bird
  • United Kingdom
  • October 30 2008

Gilead has succeeded in its appeal to the Patents Court (Mr Justice Kitchin) from the UK Intellectual Property Office, which refused the grant of an SPC in respect of a combination product comprising tenofovir and another antiretroviral, emtricitabine


New regulatory requirements in the pharmaceutical sector
  • Bird & Bird
  • European Union
  • October 30 2008

Regulation (EC) No 19012006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use (hereinafter, “the Paediatric Regulation”) is intended to tackle the problems resulting from the absence of suitably adapted medicinal products for the paediatric population (including inadequate dosage information, non-availability to the paediatric population of therapeutic advances, suitable formulations and routes of administration as well as use of magistral or officinal formulations to treat the paediatric population


Patent decisions on patents for chiral compounds
  • Bird & Bird
  • United Kingdom
  • May 13 2009

A chiral compound is one which has at least one asymmetric carbon centre


Court of Appeal explains the limited application of the Biogen principle to product claims and upholds broad product claim protection for a novel enantiomer
  • Bird & Bird
  • United Kingdom
  • May 7 2008

In a judgment given on 10 April 2008 in H. Lundbeck AS v Generics (UK) Limited & Ors, the English Court of Appeal reversed in part the decision of the Patents Court and in so doing upheld broad product claim protection for escitalopram, the () enantiomer of the racemate citalopram, and that is responsible for the SSRI activity of citalopram


Proposed reform of the generic substitution regime
  • Bird & Bird
  • Finland
  • October 16 2008

A recent governmental Bill has set out proposals for the introduction of a reference price system for medicinal products in Finland and for generic substitution to be extended to include pharmaceutical products that were excluded from the scope of generic substitution by amendment of the Medicines Act in 2006


Confidentiality in clinical trials
  • Bird & Bird
  • Netherlands
  • October 30 2008

Confidentiality covering clinical trials is important in the context of the obtaining patent protection for an invention that is the subject of a clinical trial


UK Patents Court judgment in Eli Lilly v Human Genome Sciences
  • Bird & Bird
  • United Kingdom
  • October 30 2008

The Patents Court (Mr Justice Kitchin) has, somewhat unusually, revoked a patent on the grounds of lack of industrial applicability